Integra Lifesciences Holdings Corp. (IART) financials: revenue, earnings and cash flow
Fiscal 2016–2025 + TTM · from SEC filings · data as of November 13, 2026
Summary
Integra Lifesciences Holdings’s revenue went from $992M in fiscal 2016 to $1.6B in fiscal 2025, growth of about 5.7% a year.
Net income in fiscal 2025 was -$516M, a net margin of -31.6%; the best year in this period was 2022 with $181M.
Over the twelve months to September 30, 2026, revenue was $1.7B and net income $13M.
Free cash flow was -$31M in fiscal 2025 and positive in 9 of the 10 years shown.
The diluted share count fell 3% over the period (buybacks).
Revenue, profit and cash flow by year
Income statement
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $1.7B | $1.6B | $1.6B | $1.5B | $1.6B | $1.5B | $1.4B | $1.5B | $1.5B | $1.2B | $992M |
| Gross profit | $867M | $832M | $882M | $885M | $970M | $945M | $851M | $953M | $901M | $753M | $643M |
| Operating income | $73M | -$493M | $28M | $112M | $239M | $197M | $151M | $94M | $111M | $45M | $115M |
| Net income | $13M | -$516M | -$7M | $68M | $181M | $169M | $134M | $50M | $61M | $65M | $75M |
| EPS (diluted) | $0.17 | $-6.74 | $-0.09 | $0.84 | $2.16 | $1.98 | $1.57 | $0.58 | $0.72 | $0.82 | $0.94 |
| R&D | $94M | $99M | $115M | $104M | $101M | $93M | $77M | $80M | $78M | $63M | $58M |
| Revenue growth | — | +1.5% | +4.5% | −1.0% | +1.0% | +12.4% | −9.6% | +3.1% | +23.9% | +19.8% | +12.4% |
Cash flow
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $140M | $50M | $129M | $140M | $264M | $312M | $204M | $231M | $200M | $115M | $116M |
| Capital spending | -$55M | -$81M | -$104M | -$67M | -$42M | -$48M | -$39M | -$70M | -$78M | -$44M | -$47M |
| Free cash flow | $86M | -$31M | $25M | $73M | $222M | $264M | $165M | $162M | $122M | $71M | $69M |
| Dividends paid | — | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Buybacks | $0 | $221000 | $52M | $275M | $125M | $0 | $100M | $0 | $0 | — | — |
| Stock-based pay | $20M | $19M | $24M | $20M | $28M | $36M | $20M | $21M | $21M | $22M | $17M |
Balance sheet
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash | — | $264M | $274M | $309M | $457M | $513M | $470M | $199M | $139M | $175M | $102M |
| Debt | — | $1.9B | $942M | $957M | $947M | $949M | $978M | $987M | $1.2B | $1.8B | $0 |
| Equity | — | $1.0B | $1.5B | $1.6B | $1.8B | $1.7B | $1.5B | $1.4B | $1.4B | $962M | $840M |
| Total assets | — | $3.6B | $4.0B | $3.8B | $3.9B | $3.8B | $3.6B | $3.3B | $3.1B | $3.2B | $1.8B |
| Shares (diluted) | 79M | 77M | 77M | 80M | 84M | 85M | 85M | 86M | 84M | 79M | 79M |
Margins and returns
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross margin | 52.4% | 50.9% | 54.8% | 57.4% | 62.3% | 61.2% | 62.0% | 62.8% | 61.2% | 63.3% | 64.8% |
| Operating margin | 4.4% | -30.2% | 1.8% | 7.2% | 15.3% | 12.8% | 11.0% | 6.2% | 7.5% | 3.8% | 11.6% |
| Net margin | 0.8% | -31.6% | -0.4% | 4.4% | 11.6% | 11.0% | 9.8% | 3.3% | 4.1% | 5.5% | 7.5% |
| FCF margin | 5.2% | -1.9% | 1.6% | 4.7% | 14.3% | 17.1% | 12.0% | 10.7% | 8.3% | 6.0% | 7.0% |
| ROIC | — | -15.3% | 0.9% | 3.7% | 7.3% | 5.9% | 4.8% | 3.3% | 3.4% | 1.3% | 11.3% |
| ROE | — | -49.5% | -0.4% | 4.3% | 10.0% | 10.0% | 8.8% | 3.5% | 4.4% | 6.7% | 8.9% |
Frequently asked questions
What is Integra Lifesciences Holdings’s annual revenue?
$1.6B in fiscal 2025 and $1.7B over the twelve months to September 30, 2026.
How much profit does Integra Lifesciences Holdings make?
Net income was -$516M in fiscal 2025 (net margin -31.6%).
Is Integra Lifesciences Holdings’s revenue growing?
Yes: revenue rose 1.5% in fiscal 2025 compared with the year before.
From the company’s 10-K and 10-Q filings with the SEC; per-share figures adjusted for stock splits. Rebuilt daily. Not investment advice.